Bempedoic acid (Nilemdo®) is not recommended for use within NHS Scotland for adults with primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet

In four phase III studies, the percentage reduction in LDL-C to 12-weeks was significantly larger with bempedoic acid compared with placebo; however, the company did not present sufficiently robust clinical and economic analyses to gain acceptance.

Scottish Medicines Consortium